Overview

Efficacy and Safety Trial to Evaluate the Effect of SCH 497079 on Weight in Obese and Overweight Participants (Study P05483)(COMPLETED)

Status:
Completed
Trial end date:
2009-01-30
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate the effect of SCH 497079 on weight in obese and overweight participants. The primary measure of effectiveness is the change in body weight during treatment. Additional measures include waist circumference and body mass index (BMI). In addition, the safety of SCH 497079 in obese and overweight participants will be evaluated. The primary hypothesis is that treatment with SCH 497079 will be more efficacious than that with placebo with respect to the primary efficacy variable.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Criteria
Inclusion Criteria:

- >= 18 years of age, of either sex, and of any race.

- Obese or overweight participants.

Exclusion Criteria:

- Participants who have a history of major eating disorders, gastrointestinal (GI)
surgery, active serious cardiovascular, pulmonary, endocrine, neurologic, infectious,
GI, hepatic, renal, hematologic, immunologic or psychiatric disease or diabetes.